Sunitinib (Sutent®), a small molecule inhibitor of multiple receptor tyrosine kinases (RTKs), including VEGF receptors (VEFGR), platelet-derived growth factor receptors (PDGFR), fms-related tyrosine kinase 3 (FLT3), and stem cell growth factor receptors KIT and RET [11,12], has greatly improved the outcome for metastatic ccRCC patients. Here, FLT3 is linked to nonpapillary renal cell carcinoma.